About Hema.to
Hema.to is a Healthcare company based in Munchen (Germany) founded in 2019. SaaS and AI-based software for leukemia diagnosis is developed. Hema.to has raised $7.7 million across 2 funding rounds from investors including LUMO Labs, Bayern Kapital and Elaia. Hema.to offers products and services including hema.to BASE and hema.to B-NHL. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its legal entity is hema.to GmbH.
Company details
Hema.to was founded in 2019 and is headquartered in Munich, Germany. Operations focus on the health technology sector, where SaaS platforms integrated with artificial intelligence are utilized for leukemia diagnostics. Services include software tools that assist in analyzing blood samples and identifying leukemia indicators. The company serves medical professionals through cloud-based solutions, emphasizing accuracy in diagnostic processes across European markets.
- Total Equity Funding$7.7M (USD)
in 2 rounds
- Latest Funding Round$3.78M (USD), Seed
Feb 2025
- InvestorsLUMO Labs
& 4 more
Products & Services of Hema.to
Hema.to offers a comprehensive portfolio of products and services, including hema.to BASE and hema.to B-NHL.
Automates single cell classification in cytometry for clinical diagnostics
Offers AI-based recommendations for B-NHL blood cancer diagnosis
Funding Insights of Hema.to
Hema.to has successfully raised a total of $7.7M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $3.78 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.7M
- Total Rounds 2
- Last Round Seed — $3.78M
- First Round $3.92M
(Jun 2023)
- Investors Count 5
All 2 funding rounds of Hema.to with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2025 | $3.78M | Seed | – | LUMO Labs | |
| Jun 2023 | $3.92M | Seed | – | Elaia, Heal Capital |
5 investors in total: 5 institutional.
Investors in Hema.to
Hema.to has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include LUMO Labs, Bayern Kapital and Elaia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Opportunities are created for impact-driven ventures in emerging technologies. | lumolabs.io | Eindhoven, Netherlands | ||
High-tech industries are targeted for investments by Bayern Kapital. | bayernkapital.de | Landshut, Germany | ||
Venture capital firm focused on early-stage investments | elaia.com | Paris, France | ||
Heal Capital is focused on investing in HealthTech startups. | healcapital.com | Berlin, Germany | ||
Early-stage investments are made in high-tech startups by HTGF. | htgf.de | Bonn, Germany |
Investor details for Hema.to
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Hema.to
10 people are tracked at Hema.to (5 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Felix Kunzweiler | Co-founder & CTO | Leadership |
Karsten Miermans | Chief Executive Officer | Leadership |
Daniel Moritz | CFO (interim) | Leadership |
Aleks Mężydło | Chief Medical Officer | Leadership |
Martin Becker | Head Of Medical Affairs | Leadership |
Marie Fleischmann | Legal Counsel | Team |
Felix S. | Senior Software Engineer | Team |
Alexander Trende | Senior Data And Research Scientist | Team |
Björn Biltzinger | Data & Mlops Engineer | Team |
Ali M. Abdullatif | Data Engineer | Team |
Complete people profiles for Hema.to
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Hema.to
3 dated milestones of Hema.to across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Hema.to is founded.
- Funding First funding round of $3.9M.
- Funding Latest funding round, Seed, of $3.8M.
Web traffic of Hema.to
The website of Hema.to (hema.to) receives about 2.1K visits a month.
- Monthly visits2.1K
▲ 135.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hema.To
Complete news archive for Hema.to
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hema.to
Hema.to was founded in 2019 and raised its 1st funding round 4 years after it was founded.
Hema.to is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Hema.to is a funded company, having raised a total of $7.7M across 2 funding rounds to date. The company's 1st funding round was a Seed of $3.92M, raised on Jun 2023.
Hema.to was founded in 2019 and is headquartered in Munich, Germany. Operations focus on the health technology sector, where SaaS platforms integrated with artificial intelligence are utilized for leukemia diagnostics. Services include software tools that assist in analyzing blood samples and identifying leukemia indicators. The company serves medical professionals through cloud-based solutions, emphasizing accuracy in diagnostic processes across European markets.
Hema.to offers hema.to BASE and hema.to B-NHL.
Hema.to has 5 investors. Key investors include LUMO Labs, Bayern Kapital, Elaia, Heal Capital, and High-Tech Gründerfonds.
Hema.to operates through Hema.To Gmbh.